Literature DB >> 12530061

Characterization of phosphodiesterase 3 in human malignant melanoma cell line.

Taku Murata1, Kasumi Shimizu, Motoshi Narita, Vincent C Manganiello, Toshiro Tagawa.   

Abstract

Little is known concerning the expression, distribution and function of phosphodiesterase (PDE) 3s in malignant tumor cells, including human malignant melanoma HMG and osteosarcoma HOSM-1 cells. PDE3 activity was detected in homogenates of HMG cells; however, much less activity was found in HOSM-1 cells. In HMG cells, most of the PDE3 activity was in the particulate fraction. PDE3A and 3B mRNAs were detected by RT-PCR in RNA from HMG cells only. The nucleotide sequences of the fragments were identical to those of human PDE3A and 3B. The PDE3-specific inhibitors, trequinsin and cilostamide, did not inhibit the proliferation of HMG or HOSM-1 cells. Although two PDE3 isoforms may be expressed in human malignant melanoma cells, their functional importance is not known.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12530061

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  CoMFA and CoMSIA studies of 1,2-dihydropyridine derivatives as anticancer agents.

Authors:  Ismail Salama; Mohamed A O Abdel-Fattah; Marwa S Hany; Shaimaa A El-Sharif; Mahmoud A M El-Naggar; Rasha M H Rashied; Gary A Piazza; Ashraf H Abadi
Journal:  Med Chem       Date:  2012-05       Impact factor: 2.745

Review 2.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

3.  Design, synthesis and biological evaluation of novel pyridine derivatives as anticancer agents and phosphodiesterase 3 inhibitors.

Authors:  Ashraf H Abadi; Tamer M Ibrahim; Khaled M Abouzid; Jochen Lehmann; Heather N Tinsley; Bernard D Gary; Gary A Piazza
Journal:  Bioorg Med Chem       Date:  2009-07-03       Impact factor: 3.641

Review 4.  Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets.

Authors:  F Ahmad; T Murata; K Shimizu; E Degerman; D Maurice; V Manganiello
Journal:  Oral Dis       Date:  2014-09-12       Impact factor: 3.511

5.  Active repurposing of drug candidates for melanoma based on GWAS, PheWAS and a wide range of omics data.

Authors:  Ali Khosravi; B Jayaram; Bahram Goliaei; Ali Masoudi-Nejad
Journal:  Mol Med       Date:  2019-06-20       Impact factor: 6.354

Review 6.  Targeting Cyclic AMP Signalling in Hepatocellular Carcinoma.

Authors:  Mara Massimi; Federica Ragusa; Silvia Cardarelli; Mauro Giorgi
Journal:  Cells       Date:  2019-11-25       Impact factor: 6.600

7.  Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells.

Authors:  Hiroshi Morita; Taku Murata; Kasumi Shimizu; Kenya Okumura; Madoka Inui; Toshiro Tagawa
Journal:  Oncol Rep       Date:  2013-01-31       Impact factor: 3.906

8.  Roflumilast restores cAMP/PKA/CREB signaling axis for FtMt-mediated tumor inhibition of ovarian cancer.

Authors:  Shipeng Gong; Yongning Chen; Fanliang Meng; Yadi Zhang; Huan Wu; Fei Wu
Journal:  Oncotarget       Date:  2017-12-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.